Treating hematological malignancies with cell therapy: where are we now? (Q48640926)

13 February 2018

title

Treating hematological malignancies with cell therapy: where are we now? (English)

1 reference

13 February 2018

Barbara Savoldo

1 reference

13 February 2018

author name string

Elisa Landoni

series ordinal

1 reference

13 February 2018

language of work or name

English

0 references

publication date

5 October 2017

1 reference

13 February 2018

Expert Opinion on Biological Therapy

published in

1 reference

13 February 2018

volume

1 reference

13 February 2018

issue

1 reference

13 February 2018

page(s)

65-75

1 reference

13 February 2018

Hematopoietic stem cell transplantation and cellular therapy

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Improving the safety of cell therapy with the TK-suicide gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Immunotherapy against cancer-related viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Chimeric antigen receptor-redirected T cells return to the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Design and development of therapies using chimeric antigen receptor-expressing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Immune resistance orchestrated by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Engineered T cells: the promise and challenges of cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

The onco-embryonic antigen ROR1 is expressed by a variety of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Allorecognition by T Lymphocytes and Allograft Rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Kinetics of tumor destruction by chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Optimizing T-cell receptor gene therapy for hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Transfer of specificity by murine alpha and beta T-cell receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Development of T-cell tolerance utilizes both cell-autonomous and cooperative presentation of self-antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

CD3 limits the efficacy of TCR gene therapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Survivin-specific T cell receptor targets tumor but not T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Targeting neoantigens to augment antitumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Immune checkpoint blockade in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2018.1384810

10.1080/14712598.2018.1384810

21 January 2018

Identifiers

DOI

1 reference

13 February 2018

1 reference

13 February 2018